Patients with inflammatory bowel disease demonstrate reduced HBV response

Objectives:
Data on efficacy of hepatitis-B vaccine (HBV) in patients with inflammatory bowel disease (IBD) is limited. Therefore, this review article has been conducted.

What is the efficacy of hepatitis-B vaccine (HBV) in patients with inflammatory bowel disease (IBD)?

Study design:
This review article included 14 studies with 2,375 patients.
4 data sets were available from 2 studies that compared HBV response in patients with IBD against healthy controls.

Results and conclusions:
The investigators found the pooled odds ratio of HBV response in IBD patients was 0.13 [95% CI = 0.05 to 0.33, p = 0.001].

The investigators found the pooled proportion of adequate immune response (AIR) was 64% [95% CI = 55 to 72.1, p = 0.003] from 13 data sets and effective immune response (EIR) was 39.7% [95% CI = 30.7 to 49.5, p = 0.04] from 10 data sets.

The investigators concluded that patients with inflammatory bowel disease (IBD) on immunosuppression demonstrate significantly reduced HBV response as compared with general population.

Original title:
Hepatitis-B Vaccine Response in Inflammatory Bowel Disease Patients: A Systematic Review and Meta-analysis by Kochhar GS, Mohan BP, […], Farraye F.

Link:
https://pubmed.ncbi.nlm.nih.gov/33393585/

Additional information of El Mondo:
Find more information/studies on vaccination and food fortification/malnutrition right here.